Zentalis Pharmaceuticals

Zentalis Pharmaceuticals

ZNTL· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -55.4% in FY2025

Julie Eastland is the CEO of Zentalis Pharmaceuticals and was paid $1.3M in FY2025 (Dec), down 84%.

Pay$100 in the stock at the end of FY23 → $9
CEO pay is from each Zentalis Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Andrea PaulFY2025
  2. 2Julie EastlandFY2025
  3. 3Mark Lackner, Ph.D.FY2025
  4. 4Ingmar Bruns, M.D.FY2025
  5. 5James BucherFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Zentalis Pharmaceuticals paid its 5 named executives $7.0M in total in FY2025 (Dec). CEO Julie Eastland was paid $1.3M of that.

Name
Andrea PaulFormer Chief Legal Officer and Corporate SecretaryNot disclosedNot disclosed
Julie EastlandPresident and Chief Executive OfficerNot disclosed
Mark Lackner, Ph.D.Former Chief Scientific OfficerNot disclosed
Ingmar Bruns, M.D.Chief Medical OfficerNot disclosedNot disclosed
James BucherChief Legal Officer and Corporate SecretaryNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers23

See all

The FY2023 (Dec) proxy of Zentalis Pharmaceuticals names 23 peer companies for pay. Pay versus performance data of Zentalis Pharmaceuticals for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board2

See all
  • David JohnsonDirector · 5 yr on the boardIndependentCompensation (Chair)—Paid as an executive
  • Luke Walker, M.D.Director · 1 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AApr 30, 2026FY2025
Annual report10-KMar 26, 2026FY2025
Proxy statementDEF 14AApr 30, 2025FY2024
Annual report10-KMar 26, 2025FY2024
Proxy statementDEF 14AApr 29, 2024FY2023
Annual report10-KFeb 27, 2024FY2023